

ELLISHORWOOD • PUBLISHERS

INTRODUCTORY MEDICINAL CHEMISTRY

J. B. Taylor

P. D. Kennewell

INTRODUCTORY MEDICINAL CHEMISTRY

J. B. TAYLOR, B.Sc., D.I.C., Ph.D.

Director of Pharmaceutical Research

Roussel UCLAF

Paris

and

P. D. KENNEWELL, B.A., M.A., M.Sc., Ph.D.

Deputy Head of Chemical Research and

Head of Orientative Research

Roussel Laboratories Ltd.

Swindon, Wiltshire



ELLIS HORWOOD LIMITED
Publishers · Chichester

Halsted Press: a division of

JOHN WILEY & SONS

New York · Brisbane · Chichester · Toronto

First published in 1981 by

ELLIS HORWOOD LIMITED

Market Cross House, Cooper Street, Chichester, West Sussex, PO19 1EB, England

The publisher's colophon is reproduced from James Gillison's drawing of the ancient Market Cross, Chichester.

Distributors:

Australia, New Zealand, South-east Asia:

Jacaranda-Wiley Ltd., Jacaranda Press,

JOHN WILEY & SONS INC.,

G.P.O. Box 859, Brisbane, Queensland 40001, Australia

Canada:

JOHN WILEY & SONS CANADA LIMITED

22 Worcester Road, Rexdale, Ontario, Canada.

Europe, Africa:

JOHN WILEY & SONS LIMITED

Baffins Lane, Chichester, West Sussex, England.

North and South America and the rest of the world:

Halsted Press: a division of

JOHN WILEY & SONS

605 Third Avenue, New York, N.Y. 10016, U.S.A.

© J. B. Taylor, P. D. Kennewell/Ellis Horwood Limited, Publishers 1981

British Library Cataloguing in Publication Data

Taylor, J. B.

Introductory medicinal chemistry.

1. Chemistry, Medical and pharmaceutical

I. Title II. Kennewell, P.D.

540'.2461 RS403

Library of Congress Card No. 81-6703 AACR2

ISBN 0-85312-207-5 (Ellis Horwood Limited, Publishers – Library Edn.)

ISBN 0-85312-311-X (Ellis Horwood Limited, Publishers – Student Edn.)

ISBN 0-470-27252-X (Halsted Press)

Typeset in Press Roman by Ellis Horwood Limited, Publishers

Printed in the U.S.A. by The Maple-Vail Book Manufacturing Group, New York

COPYRIGHT NOTICE –

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of Ellis Horwood Limited, Market Cross House, Cooper Street, Chichester, West Sussex, England.

Table of Contents

AUTHOR'S PREFACE	9
-------------------------------	---

CHAPTER 1 – INTRODUCTION

1.1 Definitions.....	11
1.1.1 Pharmacology.....	11
1.1.2 Molecular Pharmacology.....	12
1.1.3 Microbiology.....	12
1.1.4 Biochemistry.....	12
1.1.5 Physiology and Medicine.....	12
1.1.6 Pharmacy.....	13
1.2 Drug Development.....	13
1.2.1 Historical.....	13
1.2.2 Today.....	22
1.3 Classification.....	25
1.3.1 CNS or Psychopharmacological Agents.....	26
1.3.2 Pharmacodynamic Agents.....	26
1.3.3 Chemotherapeutic Agents.....	26
1.3.4 Metabolic Diseases and Endocrine Function.....	26
1.4 Major Processes Involved in Drug Action.....	26
1.4.1 The Pharmaceutical Phase.....	27
1.4.2 The Pharmacokinetic Phase.....	27
1.4.3 The Pharmacodynamic Phase.....	28

CHAPTER 2 – THE PHARMACEUTICAL PHASE

2.1 Introduction.....	30
2.2 Biopharmaceutics.....	30
2.3 Routes of Administration.....	32
2.3.1 The Gastro-intestinal Tract.....	32
2.3.2 Parenteral.....	36
2.3.3 Lung.....	37

2.4 Dosage Forms.	37
2.4.1 Oral Absorption.	37
2.4.2 Rectal Absorption	42
2.4.3 Parenteral Absorption	42
2.4.4 Slow-release Dosage Forms.	43
2.4.4.1 Oral Sustained Release	43
2.4.4.2 Parenteral Sustained Release.	44

CHAPTER 3 – THE PHARMACOKINETIC PHASE

3.1 The Cell.	47
3.1.1 Cell Structure	50
3.1.1.1 The Cell Membrane.	50
Lipids.	52
Proteins	52
Carbohydrates	54
Membrane Structure	54
3.1.1.2 Protoplasm – Nucleoplasm – Cytoplasm	59
3.1.1.3 The Endoplasmic Reticulum.	59
3.1.1.4 The Golgi Apparatus.	60
3.1.1.5 Lysosomes	61
3.1.1.6 Mitochondria.	61
3.1.1.7 Centrioles	61
3.1.1.8 Fibrils or Filaments	62
3.1.1.9 Microtubules	62
3.1.1.10 Vacuoles.	62
3.1.1.11 Nucleus	62
3.1.2 Entry of Materials into the Cell.	62
3.1.2.1 The Blood-Brain Barrier.	65
3.2 Quantitative Structure Activity Relationships (QSAR)	67
3.2.1 Hansch Approach to Structure-Activity Relationships	69
3.2.1.1 The Correlation with Partition Coefficient	70
3.2.1.2 Correlation with Steric Effects	78
3.2.1.3 Examples of Complex Correlations	78
3.2.1.4 The Utility of the Hansch Approach	81
3.2.2 The Topliss 'Decision-Tree' Approach	81
3.2.3 Batch Selection Methods	93
3.2.4 Bio-isosterism	94
3.2.4.1 Partial Bio-isosteres or Deceptor Groups	98

CHAPTER 4 – THE PHARMACODYNAMIC PHASE

4.1 Receptors	99
4.2 Receptor Structures.	107

4.3 Agonists and Antagonists	108
4.4 The Use of Radio-Labelled Ligands	110
4.5 The Types of Binding Involved in Drug-Receptor Interactions	114
4.5.1 Covalent Bonds	114
4.5.2 Ionic Attraction	117
4.5.3 Ion-Dipole and Dipole-Dipole Interactions	117
4.5.4 Hydrogen Bonding	117
4.5.5 Charge-Transfer Complexes	118
4.5.6 Hydrophobic Bonding	119
4.5.7 Van der Waals Forces	120
4.6 Drug-Receptor Theories	120
4.6.1 The Occupancy Theory	120
4.6.2 Rate Theory	122
4.6.3 The Induced-Fit Theory	123
4.6.4 The Macromolecular Perturbation Theory	124
4.6.5 The Activation-Aggregation Theory	124
4.7 The Topology of Receptors	126
4.8 Molecular Design	130
4.8.1 Molecules which Interact with Haemoglobin	131
4.8.2 Anti-Hypertensives	133

CHAPTER 5 – NEUROTRANSMITTERS AND RECEPTORS

5.1 The Nervous System	136
5.1.1 The Neurone	136
5.1.2 The Synapse	140
5.1.3 Electrical Transmission in Neurones	142
5.1.4 The Central Nervous System	143
5.1.5 The Peripheral Nervous System	146
5.2 Neurotransmitters	150
5.2.1 Neurotransmitters in the Peripheral System	151
5.2.2 Acetylcholine	151
5.2.3 The Neuromuscular Junction in Voluntary Nerves	152
5.2.4 Synapses in Autonomic Ganglia	155
5.2.5 Synapses in Post-Ganglionic Nerve Endings	156
5.2.6 Anti-Cholinesterases	157
5.2.7 Summary of Cholinergic System Effects	157
5.3 Catecholamines	157
5.3.1 Classification of Catecholamine Receptors	159
5.4 Neurotransmitters in the Central Nervous System	161
5.5 Summary	161

CHAPTER 6 – DRUG METABOLISM

6.1 Routes of Elimination	167
6.1.1 Kidney Function	168
6.1.2 Biliary Excretion	169
6.2 Factors Affecting Metabolism	170
6.2.1 Genetic Factors	170
6.2.2 Physiologic Factors	172
6.2.3 Pharmaceutical Factors	172
6.2.4 Drug Interactions	173
6.3 Metabolic Processes	174
6.3.1 Phase I Reactions – Functionalisation	175
6.3.1.1 Microsomal Oxidation	175
6.3.1.2 Microsomal Reductions	180
6.3.1.3 Non-Microsomal Metabolism	180
6.3.1.4 Hydrolysis	181
6.3.2 Phase II – Conjugation	182
6.3.3 Major Pathways of Drug Metabolism	186
REFERENCES	189
Selected Further Reading	190
GLOSSARY	192
INDEX	196

ELLISHORWOOD • PUBLISHERS

INTRODUCTORY MEDICINAL CHEMISTRY

J. B. Taylor

P. D. Kennewell

INTRODUCTORY MEDICINAL CHEMISTRY

J. B. TAYLOR, B.Sc., D.I.C., Ph.D.

Director of Pharmaceutical Research

Roussel UCLAF

Paris

and

P. D. KENNEWELL, B.A., M.A., M.Sc., Ph.D.

Deputy Head of Chemical Research and

Head of Orientative Research

Roussel Laboratories Ltd.

Swindon, Wiltshire



ELLIS HORWOOD LIMITED

Publishers · Chichester

Halsted Press: a division of

JOHN WILEY & SONS

New York · Brisbane · Chichester · Toronto

First published in 1981 by

ELLIS HORWOOD LIMITED

Market Cross House, Cooper Street, Chichester, West Sussex, PO19 1EB, England

The publisher's colophon is reproduced from James Gillison's drawing of the ancient Market Cross, Chichester.

Distributors:

Australia, New Zealand, South-east Asia:

Jacaranda-Wiley Ltd., Jacaranda Press,

JOHN WILEY & SONS INC.,

G.P.O. Box 859, Brisbane, Queensland 40001, Australia

Canada:

JOHN WILEY & SONS CANADA LIMITED

22 Worcester Road, Rexdale, Ontario, Canada.

Europe, Africa:

JOHN WILEY & SONS LIMITED

Baffins Lane, Chichester, West Sussex, England.

North and South America and the rest of the world:

Halsted Press: a division of

JOHN WILEY & SONS

605 Third Avenue, New York, N.Y. 10016, U.S.A.

© J. B. Taylor, P. D. Kennewell/Ellis Horwood Limited, Publishers 1981

British Library Cataloguing in Publication Data

Taylor, J. B.

Introductory medicinal chemistry.

1. Chemistry, Medical and pharmaceutical

I. Title II. Kennewell, P.D.

540'.2461 RS403

Library of Congress Card No. 81-6703 AACR2

ISBN 0-85312-207-5 (Ellis Horwood Limited, Publishers – Library Edn.)

ISBN 0-85312-311-X (Ellis Horwood Limited, Publishers – Student Edn.)

ISBN 0-470-27252-X (Halsted Press)

Typeset in Press Roman by Ellis Horwood Limited, Publishers

Printed in the U.S.A. by The Maple-Vail Book Manufacturing Group, New York

COPYRIGHT NOTICE –

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of Ellis Horwood Limited, Market Cross House, Cooper Street, Chichester, West Sussex, England.

Table of Contents

AUTHOR'S PREFACE	9
-------------------------------	---

CHAPTER 1 – INTRODUCTION

1.1 Definitions.....	11
1.1.1 Pharmacology.....	11
1.1.2 Molecular Pharmacology.....	12
1.1.3 Microbiology.....	12
1.1.4 Biochemistry.....	12
1.1.5 Physiology and Medicine.....	12
1.1.6 Pharmacy.....	13
1.2 Drug Development.....	13
1.2.1 Historical.....	13
1.2.2 Today.....	22
1.3 Classification.....	25
1.3.1 CNS or Psychopharmacological Agents.....	26
1.3.2 Pharmacodynamic Agents.....	26
1.3.3 Chemotherapeutic Agents.....	26
1.3.4 Metabolic Diseases and Endocrine Function.....	26
1.4 Major Processes Involved in Drug Action.....	26
1.4.1 The Pharmaceutical Phase.....	27
1.4.2 The Pharmacokinetic Phase.....	27
1.4.3 The Pharmacodynamic Phase.....	28

CHAPTER 2 – THE PHARMACEUTICAL PHASE

2.1 Introduction.....	30
2.2 Biopharmaceutics.....	30
2.3 Routes of Administration.....	32
2.3.1 The Gastro-intestinal Tract.....	32
2.3.2 Parenteral.....	36
2.3.3 Lung.....	37

2.4 Dosage Forms.	37
2.4.1 Oral Absorption.	37
2.4.2 Rectal Absorption	42
2.4.3 Parenteral Absorption	42
2.4.4 Slow-release Dosage Forms.	43
2.4.4.1 Oral Sustained Release	43
2.4.4.2 Parenteral Sustained Release.	44

CHAPTER 3 – THE PHARMACOKINETIC PHASE

3.1 The Cell.	47
3.1.1 Cell Structure	50
3.1.1.1 The Cell Membrane.	50
Lipids.	52
Proteins	52
Carbohydrates	54
Membrane Structure	54
3.1.1.2 Protoplasm – Nucleoplasm – Cytoplasm	59
3.1.1.3 The Endoplasmic Reticulum.	59
3.1.1.4 The Golgi Apparatus.	60
3.1.1.5 Lysosomes	61
3.1.1.6 Mitochondria.	61
3.1.1.7 Centrioles	61
3.1.1.8 Fibrils or Filaments	62
3.1.1.9 Microtubules	62
3.1.1.10 Vacuoles.	62
3.1.1.11 Nucleus	62
3.1.2 Entry of Materials into the Cell.	62
3.1.2.1 The Blood-Brain Barrier.	65
3.2 Quantitative Structure Activity Relationships (QSAR)	67
3.2.1 Hansch Approach to Structure-Activity Relationships	69
3.2.1.1 The Correlation with Partition Coefficient	70
3.2.1.2 Correlation with Steric Effects	78
3.2.1.3 Examples of Complex Correlations	78
3.2.1.4 The Utility of the Hansch Approach	81
3.2.2 The Topliss 'Decision-Tree' Approach	81
3.2.3 Batch Selection Methods	93
3.2.4 Bio-isosterism	94
3.2.4.1 Partial Bio-isosteres or Deceptor Groups	98

CHAPTER 4 – THE PHARMACODYNAMIC PHASE

4.1 Receptors	99
4.2 Receptor Structures.	107

4.3	Agonists and Antagonists	108
4.4	The Use of Radio-Labelled Ligands	110
4.5	The Types of Binding Involved in Drug-Receptor Interactions	114
4.5.1	Covalent Bonds	114
4.5.2	Ionic Attraction	117
4.5.3	Ion-Dipole and Dipole-Dipole Interactions	117
4.5.4	Hydrogen Bonding	117
4.5.5	Charge-Transfer Complexes	118
4.5.6	Hydrophobic Bonding	119
4.5.7	Van der Waals Forces	120
4.6	Drug-Receptor Theories	120
4.6.1	The Occupancy Theory	120
4.6.2	Rate Theory	122
4.6.3	The Induced-Fit Theory	123
4.6.4	The Macromolecular Perturbation Theory	124
4.6.5	The Activation-Aggregation Theory	124
4.7	The Topology of Receptors	126
4.8	Molecular Design	130
4.8.1	Molecules which Interact with Haemoglobin	131
4.8.2	Anti-Hypertensives	133

CHAPTER 5 – NEUROTRANSMITTERS AND RECEPTORS

5.1	The Nervous System	136
5.1.1	The Neurone	136
5.1.2	The Synapse	140
5.1.3	Electrical Transmission in Neurones	142
5.1.4	The Central Nervous System	143
5.1.5	The Peripheral Nervous System	146
5.2	Neurotransmitters	150
5.2.1	Neurotransmitters in the Peripheral System	151
5.2.2	Acetylcholine	151
5.2.3	The Neuromuscular Junction in Voluntary Nerves	152
5.2.4	Synapses in Autonomic Ganglia	155
5.2.5	Synapses in Post-Ganglionic Nerve Endings	156
5.2.6	Anti-Cholinesterases	157
5.2.7	Summary of Cholinergic System Effects	157
5.3	Catecholamines	157
5.3.1	Classification of Catecholamine Receptors	159
5.4	Neurotransmitters in the Central Nervous System	161
5.5	Summary	161

CHAPTER 6 – DRUG METABOLISM

6.1 Routes of Elimination	167
6.1.1 Kidney Function	168
6.1.2 Biliary Excretion	169
6.2 Factors Affecting Metabolism	170
6.2.1 Genetic Factors	170
6.2.2 Physiologic Factors	172
6.2.3 Pharmaceutical Factors	172
6.2.4 Drug Interactions	173
6.3 Metabolic Processes	174
6.3.1 Phase I Reactions – Functionalisation	175
6.3.1.1 Microsomal Oxidation	175
6.3.1.2 Microsomal Reductions	180
6.3.1.3 Non-Microsomal Metabolism	180
6.3.1.4 Hydrolysis	181
6.3.2 Phase II – Conjugation	182
6.3.3 Major Pathways of Drug Metabolism	186
REFERENCES	189
Selected Further Reading	190
GLOSSARY	192
INDEX	196

Author's Preface

The intention of the authors is to provide an introduction to the challenging world of medicinal chemistry research for those scientists entering this growing field. In particular, we realise that most entrants to the chemical research departments of pharmaceutical companies are organic chemists who may have only a minimum knowledge of the biological and pharmaceutical sciences. Moreover, all too often these people have no formalised instruction in medicinal chemistry, but are dependent upon advanced treatises on the subject and are left to 'sink or swim' in the vast sea of scientific knowledge. In such circumstances the learning process is often longer and more difficult than necessary and this can form a permanent barrier to a proper transition into medicinal chemistry.

This book arose from, and follows the format used in a course of lectures given at the City University, London. The book commences with a general introduction and then follows the idealised path of a drug from its formulation and entry into the human body, its distribution throughout the body, its interaction with possible active sites and finally, its elimination. Specific drugs are often mentioned to illustrate particular points but at all times the emphasis is on the common underlying features of the drug action. A bibliography of recommended further reading is given at the end of the book.

The ideas presented in this book have been refined and developed during discussions with Professor P. G. Sammes, Leeds University, and our colleagues at Roussel Laboratories Ltd. in Swindon and Paris, notably Robert Bucourt, Stephen Clements-Jewery, Colin Gardner, Peter Miller and Robert Westwood. Deep appreciation is due to Doreen Rarity for help with the library work, Dawn Lewis, Anne Delahousse and Patricia Taylor for the typing and Dr. J. Secchi for the photography. Finally our families are thanked for their forbearance during the gestation period required to undertake the writing of this work.

